Non-Hormonal Mechanism:
PT141 activates melanocortin receptors (MC4R and MC3R) in the brain, bypassing hormonal pathways. This makes it suitable for individuals avoiding estrogen or testosterone therapies.
Rapid Onset:
Effects manifest within 30–60 minutes post-injection, lasting 8–12 hours. This contrasts with oral medications like flibanserin, which require daily dosing and weeks to show effects.
Lyophilized Formulation:
The powder form ensures stability and extended shelf life. Reconstitution with bacteriostatic water is necessary, emphasizing proper handling to maintain sterility.
Gender-Specific Efficacy:
While studied in men for erectile dysfunction, PT141's FDA approval is specifically for premenopausal women with HSDD, highlighting its targeted application.
